RT Journal Article
SR Electronic
T1 Antibody Response to COVID-19 vaccination in Patients Receiving Dialysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.06.21256768
DO 10.1101/2021.05.06.21256768
A1 Shuchi Anand
A1 Maria E. Montez-Rath
A1 Jialin Han
A1 Pablo Garcia
A1 LinaCel Cadden
A1 Patti Hunsader
A1 Russell Kerschmann
A1 Paul Beyer
A1 Mary Dittrich
A1 Geoffrey A Block
A1 Scott D Boyd
A1 Julie Parsonnet
A1 Glenn M Chertow
YR 2021
UL http://medrxiv.org/content/early/2021/05/12/2021.05.06.21256768.abstract
AB Background Patients receiving dialysis may mount impaired responses to COVID19 vaccination.Methods We report antibody response to vaccination from 1140 patients without, and 493 patients with pre-vaccination SARS-CoV-2 RBD antibody. We used commercially available assays (Siemens) to test remainder plasma monthly in association with vaccination date and type, and assess prevalence of absent total receptor binding antibody, and absent or attenuated (index value < 10) semiquantitative receptor binding domain IgG index values. We used Poisson regression to evaluate risk factors for absent or attenuated response to vaccination.Results Among patients who were seronegative versus seropositive before vaccination, 62% and 56% were ≥65 years old, 20% and 24% were Hispanic, and 22% and 23% were Black. Median IgG index values rose steadily over time, and were higher among the seropositive than in the seronegative patients after completing vaccination (150 [25th, 75th percentile 23.2, 150.0] versus 41.6 [11.3, 150.0]). Among 610 patients who completed vaccination (assessed ≥14 days later, median 29 days later), the prevalence of absent total RBD response, and absent and attenuated semiquantitative IgG response was 4.4% (95% CI 3.1, 6.4%), 3.4% (2.4, 5.2%), and 14.3% (11.7, 17.3%) respectively. Risk factors for absent or attenuated response included longer vintage of end-stage kidney disease, and lower pre-vaccination serum albumin.Conclusions More than one in five patients receiving dialysis had evidence of an attenuated immune response to COVID19 vaccination.Significance statement Patients receiving dialysis face high likelihood of severe COVID19; at the same time, vaccination may be less efficacious, as prior data indicate impaired immune responses to influenza and Hepatitis B vaccination. We found that 22% of patients receiving dialysis had suboptimal responses to vaccination, irrespective of whether or not they had evidence of prior SARS-CoV-2 infection. Poorer health status and longer duration of end-stage kidney disease increased likelihood of suboptimal response. Ongoing vigilance for COVID19 in dialysis facilities and studies of modified vaccination dosing schedules will be critical to protecting patients receiving dialysis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr. Anand was supported by R01DK127138. Dr Chertow was supported by K24DK085446. Ascend Clinical Laboratory supported the remainder plasma testing for SARS-CoV2 antibodies.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board at Stanford University reviewed and approved the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for data will be reviewed by the authors, and data made available on a case-by-case basis.